Document is current
Any future updates will be listed below
-
Authors
da Silva Bortoleti, Bruna Taciane https://orcid.org/0000-0003-2631-6719
Quasem, Sophia
Maurer, Stefanie
Zhong, Xiaoxuan
Pimenta, Ruan https://orcid.org/0000-0002-3423-5647
Ribeiro de Lima Brandão, Luiza https://orcid.org/0000-0003-1508-3817
Hernandez, Matthew
Fraidenburg, Melanie
Alves da Silva, Pedro Henrique
Alvarez, Raymond
Chen, Benjamin K. https://orcid.org/0000-0002-5404-1997
Diniz, Márcio Augusto https://orcid.org/0000-0002-2427-7843
Housman, Brian
Flores, Raja M.
Brody, Rachel
Marron, Thomas U. https://orcid.org/0000-0001-5903-8191
Ferrari de Andrade, Lucas https://orcid.org/0000-0002-2137-2271
-
Funding
Funding for this research was provided by:
American Cancer Society (RSG-24-1188643-01-IBCD)
Elsa U. Pardee Foundation (NA)
U.S. Department of Defense (W81XWH2210262)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37CA269982)
- License Information
-
More Information
Article History
Received: 23 October 2024
Accepted: 30 September 2025
First Online: 11 November 2025
Competing interests
: L.F.d.A. and B.T.d.S.B. are named inventors in a patent that claimed F9H4 (WO2024026374A1) and filed by Mount Sinai Innovation Partners. L.F.d.A. is also named inventor in two patents that are related to 7C6 (WO2018217688A1 and WO2021072211A1) and filed through the Dana-Farber Cancer Institute; L.F.d.A. received royalty payments in relation to the antibody 7C6. L.F.d.A. also served as consultant in a translational advisory board for Cullinan MICA and has a consultancy agreement with Ono Pharmaceutical. All the other authors had no competing interests.
